MediWound Ltd. announced on September 25, 2025, that Australia’s Therapeutic Goods Administration (TGA) granted marketing authorization for NexoBrid. This approval covers the enzymatic removal of eschar in both adult and pediatric patients with deep partial- and full-thickness thermal burns.
With this regulatory milestone, NexoBrid is now authorized in 45 countries worldwide, reflecting its growing recognition as a new standard of care in burn management. MediWound’s exclusive partner in Australia, Balance Medical, expects to initiate the commercial launch in the fourth quarter of 2025.
The company's manufacturing expansion, which is on track for completion by year-end 2025, will support this launch and future global demand. This approval also opens opportunities for expansion into the broader Asia-Pacific region, where demand for advanced wound and burn treatments is increasing.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.